Clinical Trials Directory

Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

The purpose of this study is to find out the best maintenance therapy for patients with advanced stage non-small cell lung cancer. Maintenance therapy is usually given after 4 cycles of standard chemotherapy (1 cycle = 21 days) to keep the disease under control for a longer duration. This study will compare the effects, good and/or bad, of bevacizumab, pemetrexed or the combination of the two agents when given as maintenance therapy.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • biological : bevacizumab
  • drug : pemetrexed disodium

Phase: Phase 3


Ages Eligible For Study:

18 Years - N/A

External Links

Explore related trials

Contact information

Primary Contact:

Lisa Zhou 6507364112

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: